← All trials

NCT05463068

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jul 11, 2022
Primary completion
Aug 17, 2022
Completion date
Sep 1, 2022
First posted
Jul 18, 2022
Last posted
Sep 6, 2022
Enrollment
911
Arms / groups
3 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.